Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2017 2
2018 2
2019 3
2020 1
2021 13
2022 10
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.
Yu S, Chen W, Liu G, Flores B, DeWolf EL, Fan B, Xiang Y, Webber MJ. Yu S, et al. J Am Chem Soc. 2024 Mar 20;146(11):7498-7505. doi: 10.1021/jacs.3c13139. Epub 2024 Mar 11. J Am Chem Soc. 2024. PMID: 38465595
Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose. The droplets that arise are dyn …
Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when …
Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.
Thornton PS, De Leon DD, Empting S, Zangen D, Kendall DM, Birch S, Bøge E, Ivkovic J, Banerjee I. Thornton PS, et al. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1071-1079. doi: 10.1210/clinem/dgad648. J Clin Endocrinol Metab. 2024. PMID: 37930757 Free PMC article. Clinical Trial.
METHODS: In this open-label trial, patients were randomized 1:1 to SoC or SoC + dasiglucagon (10-70 g/h) for 4 weeks. In the following 4 weeks, all patients received dasiglucagon + SoC. ...Dasiglucagon appeared safe and well tolerated. Skin and gastrointestin …
METHODS: In this open-label trial, patients were randomized 1:1 to SoC or SoC + dasiglucagon (10-70 g/h) for 4 weeks. In the followin …
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial.
Nielsen CK, Øhrstrøm CC, Houji IJK, Helsted MM, Krogh LSL, Johansen NJ, Hartmann B, Holst JJ, Vilsbøll T, Knop FK. Nielsen CK, et al. Diabetes Care. 2023 Dec 1;46(12):2208-2217. doi: 10.2337/dc23-1193. Diabetes Care. 2023. PMID: 37819999 Clinical Trial.
Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea. CONCLUSIONS: Compared with placebo, 4 weeks of self-administered dasiglucagon effectively reduced clinically relevant hypoglycemia in individuals who had undergone Roux …
Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea. CONCLUSIONS: Compared with placebo, …
Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis.
Maji S, Mohanty RR, Maiti R. Maji S, et al. Balkan Med J. 2023 Oct 20;40(6):400-408. doi: 10.4274/balkanmedj.galenos.2023.2023-7-84. Epub 2023 Sep 22. Balkan Med J. 2023. PMID: 37735694 Free PMC article.
AIMS: To evaluate the efficacy and safety of dasiglucagon in insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM). ...CONCLUSION: Dasiglucagon is safer and more effective than placebo or oral glucose for insulin-induced hypoglycemia in T1DM …
AIMS: To evaluate the efficacy and safety of dasiglucagon in insulin-induced hypoglycemia in patients with type 1 diabetes mellitus ( …
Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia.
Giménez M, Khunti K, Matsuhisa M, Chenji S, Syring K, Yan Y. Giménez M, et al. Diabetes Ther. 2023 Nov;14(11):1757-1769. doi: 10.1007/s13300-023-01466-6. Epub 2023 Sep 14. Diabetes Ther. 2023. PMID: 37707700 Free PMC article. Review.
This indirect treatment comparison (ITC) evaluated the efficacy and safety differences among the three ready-to-use glucagon treatments, Baqsimi() (nasal glucagon), Gvoke() (glucagon injection) and Zegalogue() (dasiglucagon injection), in adults and children with type 1 di …
This indirect treatment comparison (ITC) evaluated the efficacy and safety differences among the three ready-to-use glucagon treatments, Baq …
Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia.
Schaumleffel C. Schaumleffel C. Patient Prefer Adherence. 2023 Aug 28;17:2141-2144. doi: 10.2147/PPA.S325865. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37663896 Free PMC article. Review.
A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the m …
A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administ …
Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report.
Reynolds D, Mitteer LM, Sigal W, Boyajian L, McKnight H, Bhatti T, States L, Becker S, Adzick NS, Lord K, De Leon DD. Reynolds D, et al. Horm Res Paediatr. 2024;97(2):187-194. doi: 10.1159/000531251. Epub 2023 Jul 14. Horm Res Paediatr. 2024. PMID: 37454652
CONCLUSION: Upon approval from the US Food and Drug Administration and the Institutional Review Board, the patient was treated with dasiglucagon, a novel soluble glucagon analog, under a single-patient Investigational New Drug. ...
CONCLUSION: Upon approval from the US Food and Drug Administration and the Institutional Review Board, the patient was treated with dasig …
42 results